News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
67,857 Results
Type
Article (10835)
Company Profile (29)
Press Release (56993)
Section
Business (16816)
Career Advice (1633)
Deals (2882)
Drug Delivery (47)
Drug Development (8526)
Employer Resources (110)
FDA (1725)
Job Trends (2135)
News (31816)
Policy (4588)
Tag
2024 Bio NC Standard (2)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (2)
2024 Genetown Standard (1)
2024 Pharm Country Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
Academia (677)
Adcomms (9)
Allergies (19)
Alliances (4466)
ALS (18)
Alzheimer's disease (205)
Antibody-drug conjugate (ADC) (28)
Approvals (1695)
Artificial intelligence (47)
Autoimmune disease (3)
Automation (3)
Bankruptcy (47)
Best Places to Work (1617)
BIOSECURE Act (10)
Biosimilars (20)
Biotechnology (22)
Bladder cancer (8)
Brain cancer (4)
Breast cancer (23)
Cancer (247)
Cardiovascular disease (27)
Career advice (1331)
Career pathing (26)
CAR-T (29)
Cell therapy (78)
Cervical cancer (2)
Clinical research (6300)
Collaboration (96)
Compensation (21)
Complete response letters (4)
COVID-19 (748)
CRISPR (11)
C-suite (30)
Cystic fibrosis (12)
Data (217)
Decentralized trials (1)
Denatured (2)
Depression (12)
Diabetes (46)
Diagnostics (651)
Digital health (3)
Diversity (3)
Diversity, equity & inclusion (29)
Drug discovery (20)
Drug pricing (45)
Drug shortages (10)
Duchenne muscular dystrophy (19)
Earnings (4708)
Editorial (31)
Employer branding (11)
Employer resources (99)
Events (7812)
Executive appointments (67)
FDA (1849)
Featured Employer (10)
Friedreich's ataxia (1)
Funding (108)
Gene editing (24)
Generative AI (7)
Gene therapy (69)
GLP-1 (195)
Government (935)
Grass and pollen (2)
Guidances (3)
Healthcare (2643)
Huntington's disease (6)
IgA nephropathy (2)
Immunology and inflammation (27)
Indications (1)
Infectious disease (770)
Inflammatory bowel disease (14)
Inflation Reduction Act (4)
Influenza (5)
Intellectual property (13)
Interviews (319)
IPO (1102)
IRA (20)
Job creations (565)
Job search strategy (1105)
Kidney cancer (2)
Labor market (18)
Layoffs (108)
Leadership (14)
Legal (1628)
Liver cancer (10)
Lung cancer (35)
Lymphoma (14)
Machine learning (2)
Management (41)
Manufacturing (53)
MASH (8)
Medical device (1270)
Medtech (1271)
Mergers & acquisitions (1805)
Metabolic disorders (152)
Multiple sclerosis (6)
NASH (4)
Neurodegenerative disease (24)
Neuropsychiatric disorders (10)
Neuroscience (294)
NextGen: Class of 2025 (1247)
Non-profit (945)
Northern California (243)
Now hiring (6)
Obesity (95)
Opinion (177)
Ovarian cancer (4)
Pain (19)
Pancreatic cancer (10)
Parkinson's disease (21)
Partnered (11)
Patents (30)
Patient recruitment (8)
Peanut (6)
People (5348)
Pharmaceutical (4)
Pharmacy benefit managers (8)
Phase I (2126)
Phase II (2751)
Phase III (2265)
Pipeline (127)
Podcasts (15)
Policy (50)
Postmarket research (250)
Preclinical (812)
Press Release (8)
Prostate cancer (13)
Psychedelics (11)
Radiopharmaceuticals (21)
Rare diseases (80)
Real estate (802)
Recruiting (45)
Regulatory (2384)
Reports (7)
Research institute (520)
Resumes & cover letters (287)
Rett syndrome (1)
RNA editing (2)
RSV (5)
Schizophrenia (17)
Series A (23)
Series B (11)
Service/supplier (1)
Sickle cell disease (14)
Southern California (240)
Special edition (7)
Spinal muscular atrophy (15)
Sponsored (10)
Startups (530)
Stomach cancer (3)
Supply chain (14)
The Weekly (13)
United States (2041)
Vaccines (190)
Venture capitalists (16)
Webinars (2)
Weight loss (89)
Women's health (8)
Worklife (13)
Date
Today (16)
Last 7 days (77)
Last 30 days (302)
Last 365 days (3733)
2025 (956)
2024 (3789)
2023 (3969)
2022 (5051)
2021 (5896)
2020 (5785)
2019 (6201)
2018 (4875)
2017 (3633)
2016 (3839)
2015 (4207)
2014 (2804)
2013 (2175)
2012 (2416)
2011 (2473)
2010 (1688)
Location
Africa (320)
Alabama (5)
Alaska (1)
Arizona (6)
Arkansas (3)
Asia (4425)
Australia (869)
California (644)
Canada (165)
China (62)
Colorado (18)
Connecticut (24)
Delaware (9)
Europe (8706)
Florida (59)
Georgia (10)
Idaho (5)
Illinois (45)
India (3)
Indiana (25)
Japan (10)
Kansas (10)
Kentucky (6)
Louisiana (2)
Maine (6)
Maryland (122)
Massachusetts (354)
Michigan (19)
Minnesota (21)
Mississippi (1)
Missouri (8)
Montana (2)
Nebraska (1)
Nevada (2)
New Hampshire (5)
New Jersey (126)
New Mexico (4)
New York (184)
North Carolina (68)
Northern California (243)
Ohio (18)
Oklahoma (3)
Oregon (4)
Pennsylvania (101)
Rhode Island (4)
South America (345)
South Carolina (1)
Southern California (240)
Tennessee (6)
Texas (92)
Utah (16)
Virginia (15)
Washington D.C. (17)
Washington State (33)
West Virginia (1)
Wisconsin (11)
67,857 Results for "hangzhou just biotherapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Patents
Just How Steep Is the Drug Patent Cliff? Ask These Pharmas
With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that have taken the leap off the patent cliff.
March 19, 2025
·
5 min read
·
Dan Samorodnitsky
Antibody-drug conjugate (ADC)
Roche Ups ADC Bet With $1B in Biobucks for Oxford BioTherapeutics
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for undisclosed cancer targets.
March 19, 2025
·
1 min read
·
Tristan Manalac
Press Releases
WORK Medical Technology Group LTD’s Subsidiary, Hangzhou Shanyou, Showcases Products at MEDICA Trade Fair 2024
November 28, 2024
·
4 min read
Deals
Broncus has announced the acquisition of the entire interest in Hangzhou Jingliang
Broncus is pleased to announce that, on November 23 2023 Broncus Hangzhou has entered into the Equity Transfer Agreement with the shareholders of the Hangzhou Jingliang, to acquire 100% equity interest in it.
November 23, 2023
·
2 min read
Press Releases
Low Doses of Antibiotic Work Just as Well as Higher Ones to Treat Rare Type of Chronic Hair Loss
March 18, 2025
·
5 min read
Rare diseases
How To Mine Biopharma’s IP Storeroom for Rare Disease Drugs, Just Like SpringWorks
SpringWorks Therapeutics is the perfect case study for rescuing a discontinued assets. It’s time to repeat the process for every rare disease, experts say.
February 26, 2025
·
5 min read
·
Annalee Armstrong
Policy
Just - Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
Evotec SE announced that its Seattle-based subsidiary, Just - Evotec Biologics, Inc., was selected by the U.S. Department of Defense to develop an accelerated monoclonal antibody development and manufacturing solution for the DOD’s Manufacturing Optimization Program.
June 25, 2024
·
7 min read
Press Releases
HIV and Syphilis Testing Just Got Faster: bioLytical Launches the 1-Minute INSTI® Multiplex HIV-1/2 Syphilis Antibody Test in Australia
March 19, 2025
·
5 min read
Business
Deep Dive: JPM M&A Rush Just the Start, as Biopharma Insider Predicts Mega-Deals to Come
The J.P. Morgan Healthcare Conference started off with a flurry of deals that reinvigorated excitement across the biopharma industry. Johnson & Johnson moved to acquire Intra-Cellular Therapies for $14.6 billion, breaking a dealmaking barrier that kept Big Pharma’s 2024 biotech buyouts to under $5 billion.
January 29, 2025
·
1 min read
·
Annalee Armstrong
Gold Colloid Co. and Hangzhou Clongene Biotech Enter Strategic Agreement to Bring Rapid In-Vitro Diagnostics and Raw Materials to the US Market
Gold Colloid Co., a leading distributor of medical and diagnostic products in the United States, announced today a strategic partnership with Hangzhou Clongene Biotech Co., Ltd., a renowned Chinese manufacturer of in-vitro diagnostic (IVD) rapid tests and raw materials.
January 12, 2024
·
2 min read
1 of 6,786
Next
